Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Giredestrant · GDC-9545, RO-7197597

Small molecule · Degrader of estrogen receptor alpha (ESR1) · developed by Hoffmann-La Roche

Phase 1/2 Most advanced trial
1 Registered trials

What is Giredestrant?

Giredestrant is an orally available selective estrogen receptor degrader that binds to the estrogen receptor and induces its degradation, preventing ER-mediated signaling. It is studied in metastatic breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GDC-9545, RO-7197597
Drug type
Small molecule
Targets
estrogen receptor alpha (ESR1)
Mechanism
Degrader of estrogen receptor alpha (ESR1)
Pathways
ER-mediated signaling
Therapy area
Oncology
Developer
Hoffmann-La Roche
In trials of
GILD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
28P3DU6DB3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03424005 Phase 1/2 Metastatic Breast Cancer Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Breast Cancer

Other drugs acting on ESR1

Camizestrant FDA approved Ethinyl Estradiol/Levonorgestrel FDA approved Imlunestrant FDA approved Segesterone Acetate and Ethinyl Estradiol FDA approved Tamoxifen FDA approved Vepdegestrant FDA approved Zuclomiphene Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.